Drawing for COVID-IGXPRESS

USPTO serial 88846406

COVID-IGXPRESS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SCHIMPF, TIMOTHY O
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with COVID-IGXPRESS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ashley Hatzenbihler

Ashley Hatzenbihler McDonnell Boehnen Hulbert & Berghoff LLP300 South Wacker Drive, Suite 3100Chicago, IL 60606United States

Goods and services

ClassDescriptionStatusFirst use
005Medical diagnostic rapid test kits primarily comprising of diagnostic test strips capable of visual or instrument read-out of test results and medical diagnostic reagents and developer solution for testing of bodily fluids and also including blood collection needles and vials, all for use in detecting antibodies, antigen, viruses, diseases, nucleic acids, pathogens and proteins; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; all the above for use in relation to COVID-19ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 15, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 15, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 15, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 15, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 15, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 6, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 5, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 1, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 6, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 6, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 16, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 3, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 3, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Sep 3, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 3, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 3, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 31, 2020DOCKASSIGNED TO EXAMINER—
Mar 29, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 27, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance